| Name | Title | Contact Details |
|---|---|---|
Greg Troiano |
Chief Manufacturing Officer and Senior Vice President of Technical Operations | Profile |
Frank DeRosa |
Chief Technology Officer | Profile |
Blue Sun Biodiesel is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.
Lifetree Pain Clinic is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Brain Cells is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kezar co-founder Christopher Kirk, Ph.D. began his work on the unique function of the immunoproteasome at Proteolix in 2005, while working on the compound that would become the successful multiple myeloma drug KYPROLIS™ (carfilzomib). As VP of Research at Onyx Pharmaceuticals, which acquired Proteolix in 2009, Christopher led the efforts to develop the first selective inhibitors of the immunoproteasome and designed multiple studies demonstrating their profound immunomodulatory effects. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. In 2014, Christopher and Kezar co-founder John Fowler began developing the business plan for Kezar, acting on a longstanding desire to work together and build a world-class company. In 2015, John and Christopher raised $23M and negotiated a worldwide, exclusive license agreement with Amgen for the Onyx immunoproteasome inhibitor patent estate. Now underway, John and Christopher are excited to leverage their complementary skill sets to build Kezar into a leader in small molecule drug development.